Ameriprise
CATX icon

Ameriprise’s Perspective Therapeutics CATX Stock Holding History

Ameriprise’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17,326
Closed -$54.7K – 4035
2024
Q4 		$54.7K Sell
17,326
-645,170
-97% -$5.27M ﹤0.01% 4002
2024
Q3 		$8.84M Buy
+662,496
New +$8.81M ﹤0.01% 1899
2024
Q2 		– Sell
-9,320
Closed -$111K – 3871
2024
Q1 		$111K Buy
9,320
+7,820
+521% +$66.7K ﹤0.01% 3771
2023
Q4 		$6.03K Hold
1,500
– – ﹤0.01% 3885
2023
Q3 		$4.11K Hold
1,500
– – ﹤0.01% 3882
2023
Q2 		$10K Hold
1,500
– – ﹤0.01% 3893
2023
Q1 		$9.57K Hold
1,500
– – ﹤0.01% 3916
2022
Q4 		$4K Hold
1,500
– – ﹤0.01% 3946
2022
Q3 		$3K Sell
1,500
-300
-17% -$1.03K ﹤0.01% 3945
2022
Q2 		$6K Hold
1,800
– – ﹤0.01% 3873
2022
Q1 		$7K Hold
1,800
– – ﹤0.01% 3920
2021
Q4 		$7K Buy
+1,800
New +$9.6K ﹤0.01% 3949
2021
Q1 		– Sell
-2,000
Closed -$9K – 3841
2020
Q4 		$9K Buy
+2,000
New +$8.84K ﹤0.01% 3751

Other funds holding CATX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $170M AUM 10.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Ameriprise's CATX Position: Q1 2025 in Review

Ameriprise sold out of Perspective Therapeutics (CATX) in Q1 2025, closing a stake of 17,326 shares — an estimated $54.7K sold.

Ameriprise first reported a position in CATX in Q4 2020 and held it in 13 quarters. The position peaked at $8.84M in Q3 2024. 112 funds tracked by Wall St. Rank hold CATX as of Q1 2025.

  • Ameriprise reported no remaining Perspective Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Ameriprise sold 17,326 Perspective Therapeutics shares in Q1 2025, an estimated $54.7K.
  • Ameriprise first reported a position in Perspective Therapeutics in Q4 2020 and held it in 13 quarters.
  • Ameriprise's Perspective Therapeutics position peaked at $8.84M in Q3 2024.
  • 112 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2025.

Based on Ameriprise's 13F filing for Q1 2025, filed 14 May 2025.